Navigation Links
Health risks after cessation of postmenopausal hormone therapy
Date:3/4/2008

The Womens Health Initiative (WHI) investigators have produced another article [1], which probably marks the opening of another set of publications, in which the consequences of a further 2.4-year follow-up (after cessation of the study medication) on the estrogen + progestogen (E + P) cohort are reported. They concluded that, by the end of the post-intervention period, the global index, a newly formed and unvalidated tool used in the WHI trial, was still higher in women randomly assigned to receive E + P compared with placebo.

After such long and painful debates over the results of the WHI study and the perception that age is a very important determinant of the benefitrisk evaluation, it is really a pity that once again the current information on the extended follow-up period is presented in an unsatisfactory way, says Professor Amos Pines, the President of the International Menopause Society. It seems that the following mistakes were repeated:

  1. There is no mention of the results by age groups and yet, for the age group 5059 years, the data recorded for the active phase of the WHI E + P arm showed no significant increase in risk of coronary events, strokes and breast cancer in the early postmenopause period. Also, there is no breakdown of the data by years of follow-up. It would be extremely important to know whether the results for the first year post cessation of therapy are similar to those for year 2 and year 3 of follow-up.
  2. The breast cancer results for first-time users of E + P were not presented, whereas breast cancer risk during the active phase of the WHI was similar to that of the placebo group in women with no prior use of E + P.
  3. There is little relevance in the presentation of the combined results for the active phase and the follow-up phase, since it has no real scientific importance. Combining the two periods and grouping the outcomes (all cancers, all cardiovascular events) helped the authors to show significance in some of the variables. However, the overall differences in the annualized rates between the E + P arm and the placebo arm were in the order of 1.5 cardiovascular events per 1000 women/year and 1.2 cancers per 1000 women/year. Again, no data were shown for the younger age group.

It seems that the WHI investigators have forgotten the turmoil and anxiety they caused in 2002 when they published the preliminary results of the E + P cohort, concluded Professor Pines. By releasing the new data without performing all the necessary, important sub-analyses, women could face another unjustified turmoil related to hormone therapy.


'/>"/>

Contact: Dr. David Sturdee
david.sturdee@btinternet.com
International Menopause Society
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2019)... ... January 14, 2019 , ... The Centers ... of VARIZIG® (Varicella Zoster Immune Globulin [Human]) for post-exposure prophylaxis of varicella ... update, the CDC notes that VARIZIG is commercially available from a broad network ...
(Date:1/13/2019)... ... January 12, 2019 , ... New Vitae ... year of service to the community, providing a variety of residential behavioral health ... anniversary,” said New Vitae co-founder and owner Adam Devlin. “We are continuing ...
(Date:1/11/2019)... , ... January 11, 2019 , ... ... three finalist teams in its “Next Generation Captive Insurance Solutions for New Risk ... Risk Solutions. , The three finalist teams are: , ...
(Date:1/10/2019)... , ... January 10, 2019 , ... On Tuesday, January 8, Dr. Samuel Joseph, ... in the world to use Osseus Fusion Systems revolutionary 3D Printed Aries ... development process and see your ideas brought to life so quickly,” commented Dr. Joseph, founder ...
(Date:1/8/2019)... ... January 08, 2019 , ... West 10th Dental in New York, NY is ... According to Dr. Demetrios Sengos, founder of West 10th Dental, "We want our patients ... dental care by always keeping up with the latest in technology as dentistry changes, ...
Breaking Medicine News(10 mins):
(Date:1/11/2019)... Texas (PRWEB) , ... January 11, 2019 , ... Proven ... gyms across the United States by 2024. Hartl, who previously built the ... in Killeen and Waco , Texas. , “It’s why I came ...
(Date:1/11/2019)... ... January 11, 2019 , ... ... ranked among the top US security companies for consecutive years, proudly announces their ... This award recognizes companies that excel at employee relations, use innovation to motivate ...
(Date:1/10/2019)... BALTIMORE (PRWEB) , ... January 10, 2019 , ... ... a new office location in Baltimore, Maryland. The new location, at 312 Martin ... second office, and home to a growing team of healthcare professionals. , Dr. ...
Breaking Medicine Technology: